In a still-recruiting phase I/II trial, NEXI-001 T-Cells with the targets PRAME/WT1/Cyclin A1 are infused after alloHSCT in AML or MDS patients with the goal of enhanced GvL effect without increasing the incidence of GvHD, cytokine release syndrome or neurotoxicity (NCT04284228; [91]). The gene discussed is PRAME; the disease is acute myeloid leukemia.